Union Bancaire Privee UBP SA Invests $74.55 Million in Danaher Co. (NYSE:DHR)

Union Bancaire Privee UBP SA purchased a new stake in shares of Danaher Co. (NYSE:DHR) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 327,201 shares of the conglomerate’s stock, valued at approximately $74,551,000. Danaher comprises about 1.5% of Union Bancaire Privee UBP SA’s investment portfolio, making the stock its 18th largest position.

A number of other hedge funds and other institutional investors have also bought and sold shares of DHR. FMR LLC increased its stake in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after acquiring an additional 535,254 shares during the last quarter. International Assets Investment Management LLC boosted its holdings in shares of Danaher by 40,196.5% during the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after purchasing an additional 428,897 shares during the period. Montrusco Bolton Investments Inc. grew its stake in shares of Danaher by 30.4% in the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after purchasing an additional 397,671 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec raised its position in Danaher by 82.4% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 653,375 shares of the conglomerate’s stock valued at $181,651,000 after purchasing an additional 295,187 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Evercore ISI boosted their price objective on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. TD Cowen raised their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Royal Bank of Canada reduced their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Guggenheim initiated coverage on Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price on the stock. Finally, KeyCorp lifted their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $285.55.

Danaher Trading Up 0.1 %

Danaher stock opened at $245.95 on Monday. Danaher Co. has a 1 year low of $225.42 and a 1 year high of $281.70. The firm’s 50 day moving average price is $235.33 and its 200-day moving average price is $253.54. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The stock has a market cap of $177.65 billion, a P/E ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.